The study also showed an increased expression of CTLA4 and HAVCR2 in CRC in the presence of MSI, suggesting an opportunity for potential use of certain checkpoint inhibitors (CTLA4 and HAVCR2 inhibitors) in CRC with MSI. Here, CTLA4 is linked to colorectal carcinoma.